Published date: 21 October 2019

Last edited date: 3 March 2020

This notice was replaced on 10 July 2020

This notice does not contain the most up-to-date information about this procurement. The most recent notice is:

Awarded contract (published 10 July 2020)

Closed opportunity - This means that the contract is currently closed. The buying department may be considering suppliers that have already applied, or no suitable offers were made.


Contract summary

Industry

  • Pharmacy services - 85149000

Location of contract

East of England, London, South East

Value of contract

£36,000,000

Procurement reference

tender_215833/799194

Published date

21 October 2019

Closing date

9 March 2020

Contract start date

1 July 2020

Contract end date

30 June 2021

Contract type

Supply contract

Procedure type

Open procedure (above threshold)

Any interested supplier may submit a tender in response to an opportunity notice.

This procedure can be used for procurements above the relevant contract value threshold.

Contract is suitable for SMEs?

Yes

Contract is suitable for VCSEs?

No

Description

NHS Framework Agreement for Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - East of England, London and South East Coast.
Offer reference number: CM/PHS/19/5580
Period of framework agreement: 1 July 2020 - 30 June 2021 with options to extend up to a further 36 months. Total maximum framework agreement including extension options will be no more than 48 months

More information

Attachments

Additional text

Document No.05a - Offer Schedule, published on Bravo, has been amended and an updated version, Document No.05a - Offer Schedule (Reissue), has been published on Bravo today. The revised document reflects changes made to the listed Bevacizumab products which were incorrectly listed as pre-filled syringes instead of infusion bags. Please ensure you used the updated document when submitting your offer.
Document No.05a - Offer Schedule (Reissue) published on Bravo, has been amended and an updated version, Document No.05a - Offer Schedule (Reissue v2) has been published on Bravo today. The revised document reflects changes made to the "low volume product" list which incorrectly included Pertuzumab. In addition, the estimated total annual usage in single units (NoE) was blanked out for products that are not being awarded to that region under this tender. The cells have been cleared of data in the updated version. Please ensure you use the updated document when submitting your offer.
Document No.05c - Award Methodology and Criteria, published on Bravo, has been amended and an updated version, Document No.05c - Award Methodology and Criteria (Reissue) has been published on Bravo today. The revised document reflects changes made to the "low volume product" list which incorrectly included Pertuzumab. Please ensure you use the updated document when submitting your offer.
Document No.04e - Standard Product Specifications published on Bravo, has been amended and an updated version, Document No.04e - Standard Product Specification (Reissue) has been published on Bravo today. The revised document reflects a change made to the Bortezomib specification which now states "Licensed Bortezomib injection". In addition, the revised document reflects a change made to the Ganciclovir specification which now states volume of "50ml or 100ml". Please ensure you used the updated document when submitting your offer.
Document No.03 - Framework Agreement and Terms and Conditions, published on Bravo, has been amended and an updated version, Document No.03 - Framework Agreement and Terms and Conditions (Reissue), has been published on Bravo today. The revised document reflects a change made to the Ordering Procedure (Schedule 7) paragraph 1.2.2 which now states "send an Order to the Framework Provider as set out in clause 3 of this Schedule 7 following the evaluation of its Offer". Please ensure you refer to the updated document when submitting your offer.
Document No.05a - Offer Schedule (Reissue v2), published on Bravo, has been amended and an updated version, Document No.05a - Offer Schedule (Reissue v3), has been published on Bravo today, 3 March 2020. The revised document reflects changes made under 'Tab 2 Pricing Schedule'. These changes indicate that under the heading Product Description, the eleven rows indicating Nivolumab 120mg to 480mg (inclusive) should read /100ml - not /50ml as previously advised.

About the buyer

Address

Commercial Medicines Unit, Rutland House
Runcorn
WA7 2AA
England

Email

darryn.boardman@nhs.net